What 15 Analyst Ratings Have To Say About Blueprint Medicines
Portfolio Pulse from Benzinga Insights
In the last quarter, 15 analysts have provided ratings for Blueprint Medicines (NASDAQ:BPMC), with 6 being bullish, 3 somewhat bullish, 5 indifferent, and 1 somewhat bearish. The company has an average 12-month price target of $69.6, which has increased by 20.37% over the past month.
August 04, 2023 | 11:53 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Blueprint Medicines has received mostly positive ratings from analysts, with an increasing price target.
The majority of the 15 analysts have given bullish or somewhat bullish ratings for Blueprint Medicines, indicating a positive outlook for the company. Additionally, the average 12-month price target has increased by 20.37% over the past month, suggesting that analysts believe the stock price will rise in the future.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100